Codiak BioSciences focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology and neurology. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutic S.A. and Washington University.
Market Cap | 2.099 Million | Shares Outstanding | 36.83 Million | Avg 30-day Volume | 3.881 Million |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.77 |
Price to Revenue | 0.5775 | Debt to Equity | 0.66 | EBITDA | -10.66 Million |
Price to Book Value | 0.5054 | Operating Margin | -156.4635 | Enterprise Value | -6.394 Million |
Current Ratio | 4.236 | EPS Growth | -1.071 | Quick Ratio | 3.581 |
1 Yr BETA | 1.3548 | 52-week High/Low | 6.98 / 0.05 | Profit Margin | -51.1301 |
Operating Cash Flow Growth | 22.4437 | Altman Z-Score | -3.3161 | Free Cash Flow to Firm | -89.192 Million |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
HOWZE YALONDA SEE REMARKS |
|
7,458 | 2023-03-30 | 5 |
BARNA NICOLE SEE REMARKS |
|
4,849 | 2023-03-29 | 5 |
SATHYANARAYANAN SRIRAM CHIEF SCIENTIFIC OFFICER |
|
0 | 2023-03-29 | 5 |
WILLIAMS DOUGLAS E PRESIDENT & CEO |
|
7,655 | 2023-03-28 | 4 |
BAIN LINDA CHIEF FINANCIAL OFFICER |
|
0 | 2023-03-28 | 5 |
KONSTANTINOV KONSTANTIN CHIEF TECHNOLOGY OFFICER |
|
0 | 2023-03-28 | 5 |
|
8,750 | 2023-02-16 | 2 | |
|
15,350 | 2023-02-16 | 2 | |
|
8,750 | 2023-02-16 | 3 | |
|
8,750 | 2023-02-16 | 2 | |
|
8,750 | 2023-02-16 | 2 | |
MAURO DAVID J CHIEF MEDICAL OFFICER |
|
190,000 | 2023-01-24 | 2 |
FLAGSHIP VENTURES FUND V GENERAL PARTNER LLC FLAGSHIP VENTURES FUND V, L.P. |
|
3,540,636 | 2022-09-15 | 1 |
ARCH VENTURE FUND VIII OVERAGE, L.P. |
|
8,854,098 | 2022-09-13 | 1 |
|
9,000 | 2022-06-17 | 1 | |
|
9,000 | 2022-06-17 | 1 | |
BRUDNICK RICHARD SEE REMARKS |
|
27,125 | 2022-02-16 | 0 |
SORENSEN BENNY SEE REMARKS |
|
87,411 | 2021-06-08 | 0 |
WHELER JENNIFER J. CHIEF MEDICAL OFFICER |
|
100,000 | 2021-05-10 | 0 |
|
4,761 | 2021-02-17 | 0 | |
VERMA AJAY SEE REMARKS |
|
0 | 2021-01-22 | 0 |
|
27,077,370 | 2020-10-16 | 0 | |
|
738,134 | 2020-10-13 | 0 | |
FLAGSHIP VENTURES FUND V GENERAL PARTNER LLC FLAGSHIP VENTURELABS V MANAGER LLC FLAGSHIP VENTURES FUND V, L.P. |
|
485,949 | 2020-10-13 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
CODIAK BIOSCIENCES INC CDAKQ | 2023-05-31 22:15:04 UTC | -26.9226 | 31.9826 | 1100000 |
CODIAK BIOSCIENCES INC CDAKQ | 2023-05-31 21:45:04 UTC | -26.9226 | 31.9826 | 1100000 |
CODIAK BIOSCIENCES INC CDAKQ | 2023-05-31 21:15:03 UTC | -26.9226 | 31.9826 | 1100000 |
CODIAK BIOSCIENCES INC CDAKQ | 2023-05-31 20:45:04 UTC | -26.9226 | 31.9826 | 1100000 |
CODIAK BIOSCIENCES INC CDAKQ | 2023-05-31 20:15:06 UTC | -26.9226 | 31.9826 | 1100000 |
CODIAK BIOSCIENCES INC CDAKQ | 2023-05-31 19:45:04 UTC | -26.9226 | 31.9826 | 1100000 |
CODIAK BIOSCIENCES INC CDAKQ | 2023-05-31 19:15:21 UTC | -26.9226 | 31.9826 | 1100000 |
CODIAK BIOSCIENCES INC CDAKQ | 2023-05-31 18:45:03 UTC | -26.9226 | 31.9826 | 1100000 |
CODIAK BIOSCIENCES INC CDAKQ | 2023-05-31 18:15:04 UTC | -26.9226 | 31.9826 | 1100000 |
CODIAK BIOSCIENCES INC CDAKQ | 2023-05-31 17:45:03 UTC | -26.9226 | 31.9826 | 1100000 |
CODIAK BIOSCIENCES INC CDAKQ | 2023-05-31 17:15:05 UTC | -26.9226 | 31.9826 | 1100000 |
CODIAK BIOSCIENCES INC CDAKQ | 2023-05-31 16:45:04 UTC | -26.9255 | 31.9955 | 1100000 |
CODIAK BIOSCIENCES INC CDAKQ | 2023-05-31 16:15:04 UTC | -26.9255 | 31.9955 | 1100000 |
CODIAK BIOSCIENCES INC CDAKQ | 2023-05-31 15:45:03 UTC | -26.9255 | 31.9955 | 1100000 |
CODIAK BIOSCIENCES INC CDAKQ | 2023-05-31 15:15:04 UTC | -26.9255 | 31.9955 | 1100000 |
CODIAK BIOSCIENCES INC CDAKQ | 2023-05-31 14:45:04 UTC | -26.9255 | 31.9955 | 1100000 |
CODIAK BIOSCIENCES INC CDAKQ | 2023-05-31 14:15:03 UTC | -26.9255 | 31.9955 | 1100000 |
CODIAK BIOSCIENCES INC CDAKQ | 2023-05-31 13:45:04 UTC | -26.9255 | 31.9955 | 1100000 |
CODIAK BIOSCIENCES INC CDAKQ | 2023-05-31 13:15:04 UTC | -26.9255 | 31.9955 | 1100000 |
CODIAK BIOSCIENCES INC CDAKQ | 2023-05-31 12:45:04 UTC | -26.9255 | 31.9955 | 1100000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|